TAILORx Tissue Bank

December 15, 2025 updated by: Cancer Trials Ireland

Breast Cancer Bank of Tissue From Trial Assigning Individualized Options for Treatment (TAILORx Tissue Bank)

This is an exploratory, translational, non-interventional and multi-centre biobank. The aim of the development of such a biobank is to identify potential biomarkers that are indicative of disease relapse.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

The primary objective is to develop a biobank, tissue microarrays (TMAs) and full face sections, which will be used to identify candidate/ novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance.

The secondary objectives are:

  • To validate emerging signatures/biomarkers identified.
  • To develop new assays for the breast cancer clinic.

Study Type

Observational

Enrollment (Actual)

600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Ireland
      • Cork, Ireland
        • Cork University Hospital
      • Cork, Ireland
        • Bons Secours Hospital
      • Donegal, Ireland
        • Letterkenny General Hospital
      • Dublin, Ireland
        • Mater Misericordiae University Hospital
      • Dublin, Ireland, 9
        • Beaumont Hospital
      • Dublin, Ireland, 8
        • St James Hospital
      • Dublin, Ireland, 24
        • Adelaide and Meath National Children's Hospital Tallaght
      • Dublin, Ireland, 4
        • St Vincent Universtiy Hospital
      • Galway, Ireland
        • Galway University Hospital
      • Limerick, Ireland
        • Midwestern Regional Hospital
      • Sligo, Ireland
        • Sligo General Hosptial
      • Waterford, Ireland
        • Waterford Regional Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population will consist only of patients that participated in the TAILORx ICORG 06-31 trial. These patients must have participated in trial arms relevant to ICORG 06-31 study and have adequate tumour tissue available.

Description

Inclusion Criteria:

  • Patients that were registered with the ICORG 06-31 TAILORx trial and participated in trial arms
  • Patients with adequate tumor tissue available

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
TAILORx ICORG 06-31
Patients must have participated in TAILORx ICORG 06-31, participated in trial arms, and have adequate tumour tissue available

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Disease relapse, endocrine and/or chemotherapy resistance prognosis
Time Frame: For duration of follow up, expected 10 years
A biobank, TMAs and full face sections, will allow for the identification of candidate/novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance
For duration of follow up, expected 10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Signature/biomarkers
Time Frame: For the duration of follow up, expected 10 years
Validation of emerging signature/biomarkers
For the duration of follow up, expected 10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cancer Trials Ireland

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2013

Primary Completion (Actual)

December 1, 2020

Study Completion (Estimated)

November 1, 2031

Study Registration Dates

First Submitted

January 24, 2014

First Submitted That Met QC Criteria

January 30, 2014

First Posted (Estimated)

January 31, 2014

Study Record Updates

Last Update Posted (Estimated)

December 19, 2025

Last Update Submitted That Met QC Criteria

December 15, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ICORG 12-30

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe